Zoetis delivered solid Q4 2025 results, reporting 3% revenue growth and 5.7% EPS growth, alongside a strong 27%+ non-GAAP net margin, surpassing market expectations. The company benefits from broad diversification across animal health products and balanced U.S. and international sales. Looking ahead, Zoetis plans to launch next-generation osteoarthritis drugs Portela and Lenivia in 2026, aiming to improve patient compliance and expand market share. Trading at a 25% discount to fair value with an 8.4% EPS growth forecast, Zoetis is positioned for attractive annualized returns of 14%–37% through 2031.
Pomerantz LLP has filed a class action lawsuit against Zoetis Inc., alleging securities fraud and other unlawful practices following the company's announcement of a profit guidance cut for 2026. Zoetis reported flat net income of $601 million for Q1 ...
Pomerantz LLP has filed a class action lawsuit against Zoetis Inc., alleging securities fraud linked to the company's lowered 2026 profit guidance and a significant stock price drop. Zoetis reported flat net income for Q1 2026 and reduced its full-ye...
Zoetis, once a high-performing stock, has fallen about 70% from its peak in December 2021, mainly because its U.S. companion animal business saw an 11% organic decline in Q1 2026 after strong growth in 2021. The decline is linked to weaker U.S. consu...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
